People who underwent a minimally invasive procedure to have their heart's aortic valve replaced had similar health outcomes ...

Edwards Lifesciences Corp. (($EW)) announced an update on their ongoing clinical study. Study Overview: Edwards Lifesciences Corp. is conducting ...

The DapaTAVI trial previously showed reduced rates of death or worsening heart failure with dapagliflozin in older adults with aortic stenosis undergoing transcatheter aortic valve implantation (TAVI) ...

WILLIAMSPORT, Pa. — Aortic stenosis is a condition that often develops with age. It's caused by a buildup of calcium, which causes the aortic valve to become too narrow, reducing blood flow from the ...

Please provide your email address to receive an email when new articles are posted on . TAVR did not improve a composite of clinical endpoints in patients with moderate aortic stenosis and HFrEF.

The new system offers surgeons a larger coronary access window and increased space to facilitate access to a patient’s coronary arteries. This leads to lower mortality rates, lower stroke rates and ...

Among female patients with aortic stenosis, angiotensin II receptor blockers (ARBs) may help reduce fibrosis of the aortic valve. A retrospective study aimed to determine whether a sex-specific ...

WASHINGTON--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced results from the EARLY TAVR Trial, the first randomized, controlled trial designed to study the best strategy for treating ...

Please provide your email address to receive an email when new articles are posted on . The FDA granted breakthrough device designation to AccurKardia’s AI-powered aortic valve stenosis screening ...

Aortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally. Researchers at Mayo Clinic are exploring the use of a new drug called ...